Effectiveness of AMD3100 in treatment of leukemia and solid tumors: from original discovery to use in current clinical practice

AMD3100, also known as plerixafor, was originally developed as an anti-human immunodeficiency virus (HIV) drug, and later characterized as a C-X-C chemokine receptor type 4 (CXCR4) antagonist. Previous reviews have focused on the application of AMD3100 in the treatment of HIV, but a comprehensive ev...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Tao, Li, Xiaobo, You, Shuo, Bhuyan, Soumitra S., Dong, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4947283/
https://www.ncbi.nlm.nih.gov/pubmed/27429863
http://dx.doi.org/10.1186/s40164-016-0050-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4947283/
https://www.ncbi.nlm.nih.gov/pubmed/27429863
http://dx.doi.org/10.1186/s40164-016-0050-5

Ejemplares similares